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The aim of study was to investigate the expression of the proliferation factor Ki-67 and its relationship with histological grade,
cancer stage, and treatment outcome in squamous cell carcinoma of the larynx. Samples from 78 patients with laryngeal cancer
were analysed retrospectively. Paraffin sections of tumors were immunohistochemically stained for Ki-67 expression. The patients
were divided in two groups according to the proliferative factor values (a low Ki-67 index group - Ki-67≤34 and high Ki-67 index
group-Ki-67 >34). Statistical analysis of the data shows significant correlation among histological tumor grade and the value of
the Ki-67 proliferative index. There was no correlation between tumoral Ki-67 expression and diagnosis, stage of the disease, or
treatment outcome. In conclusion, Ki-67 expression in laryngeal cancer is not themost reliablemarker formaking precise diagnosis
and predicting the clinical course.
1. Introduction
Malignant neoplasms of the larynx are the most common
malignancies of the upper respiratory tract in adults [1].
The biggest treatment challenge is to predict the course of
the disease and develop a treatment plan accordingly. Great
efforts have been made in order to determine the relevance
of potential prognostic factors, including clinical stage, site
and size of the tumor, histological grade, and depth of tumor
invasion. To date, however, none of the parameters have
either proven to be reliable or to have any irrefutable clinical
value as a prognostic factor [2]. Treatment planning relies
on histopathological diagnosis and assessment of the tumor-
nodus-metastasis (TNM) stage. A precise histolopathological
grading of neoplasms is extremely important for a reliable
prognosis but we must be aware of nonstandardized criteria
resulting in poor precision of this tool [3]. On the other hand,
TNM provides prognostic information that guides treatment
for cohorts of patients with laryngeal cancer but is limited by
its inability to predict success on an individual basis [4].
An important feature of malignant transformation is the
deregulation of the cell cycle as shown by a large number
and high proliferation rate of dividing cells. In a number of
studies, several approaches have been adopted to determine
the proliferative activity of tumor tissue as accurately as
possible.Themeasurement has included the determination of
the S-phase fractions, mitotic index, and histone H3 mRNA
[5–7]. Most of the studies have produced contradictory
results on proliferative activity and disease prognosis [8].
More reliable results have been obtained using Ki-67 as a
proliferation marker [6, 9].
Ki-67 is a nuclear protein that is responsible for cell
proliferation. It is only expressed in the cell division cycle:
interphase (G1, S, and G2), prophase, metaphase, anaphase,
and telophase. Its expression is absent in the G0 phase,and,
therefore, Ki-67 is an excellent marker of cell division [10].
The results of the study by De Vincentiis and Bai demon-
strated increased expression of the Ki-67 proliferative index
in both patients with poorly differentiated carcinomas and
patients with regional lymph node metastases [11, 12]. In
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contrast to the above, these results were not confirmed by
other authors [13, 14]. Ki-67 expression correlates positively
with tumor grade and pathological stage of the disease [2, 14].
Acikalin et al. found a significant correlation between Ki-67
expression and patient age and tumor stage and lymph node
metastases [15]. A study of a cohort of 4,806 patients demon-
strated a correlation between Ki-67 expression and disease
prognosis [6]. Gioacchini et al. performed a systematic review
on articles dealingwith Ki-67 immunohistochemical staining
and laryngeal squamous cell carcinoma.Their review strongly
suggests that immunohistochemical staining of Ki-67 cor-
relates with tumoral aggressiveness and worse prognosis in
patients [16]. Ki-67 can be used as an important indicator for
judging clinical progress and estimating prognosis in human
laryngeal squamous carcinoma [12].
The aim of this study is to investigate the expression
of the proliferation factor Ki-67 and its relationship with
histological grade, cancer stage, and treatment outcome in
squamous cell carcinoma of the larynx. This will enable us
to develop our own opinion on benefits of the proliferation
factorKi-67 in diagnosis, treatment, and follow-up of patients
with malignant tumors of the larynx.
2. Materials and Methods
2.1. Materials. A retrospective study was performed on 78
tissue samples from patients with laryngeal cancer.The study
included patients diagnosed with squamous cell carcinoma
of the larynx. The patients were divided into two groups. The
first group consisted of 68 (87.2%) patients diagnosed with
laryngeal cancer, and the second group included 10 (12.8%)
patients with laryngeal cancer and regional lymph node
metastases.The patients’ age at diagnosis ranged from45 to 81
years, with themedian of 60 years. All the patients underwent
surgical treatment. A partial laryngectomy was performed in
36, and 42 patients were submitted to a total laryngectomy. A
total of 55 patients underwent oncology treatment: radiation
therapy alonewas administered to 47 and chemoradiotherapy
to 8 patients. Patients were further divided according to the
stage of their disease. As literature suggests, stages 1 and 2
were considered early stage, and stages 3 and 4 were classified
as advanced stage [17].There were 36 (46.2%) and 42 (53.8%)
patients in the early and advanced stage of the disease,
respectively. As regards histological grade, the patients were
divided into four groups. Patients with histological grade 2
(51.3%) accounted for the largest share, followed by patients
with grade 1 (23.1%) and then those with grade 3 (14.1%),
whereas the share of grade 0 tumor patients was the smallest
(11.5%). For all patients, information on local recurrence,
regional lymph node metastases, and occurrence of a second
primary tumor was collected from their medical records.
Local recurrence was reported in 8 (10.2%) patients, regional
lymph node metastases were reported in 9 (11.5%), and a
second primary tumor was found in 7 (9.0%) patients. The
patients were followed up for 5 years after surgery. The total
number of patients alive after 5 years was 50 (64.1%). Given
that this was a bench research study, there was no need to
establish a control group.
2.2. Methods. Tissue samples of invasive and in situ squa-
mous cell carcinoma were stained by immunohistochem-
istry. Histopathological analysis was performed using light
microscopy. All the specimens were fixed in 10% buffered
formalin (Kemika, Zagreb, Croatia), embedded into paraffin
blocks, and stained with hematoxylin and eosin (HE). The
specimens were determined for the degree of histologic
differentiation according to the World Health Organization
grading scheme.
2.3. Immunohistochemical Analysis. Representative tissue
samples of laryngeal carcinoma were selected to make a
paraffin block further cut into into 4-5𝜇m thick sections.
Overnight, sections were kept in a thermostat at 37∘C, then
deparaffinized using the standard procedure with a xylene
substitute (Tissue Clear Sakura) (3x10󸀠), and rehydrated in
absolute ethyl alcohol (2x5󸀠), 96% ethyl alcohol (5󸀠), and
70% ethyl alcohol (5󸀠) until washed with distilled water.
The samples were treated using the EnVision method-based
visualization system. The visualization system (Dako Real
EnVisionDetection SystemPeroxidase/DAB+, Rabbit/Mouse
K5007) was used with an automated immunostainer (Dako
Autostainer Plus). Diaminobenzidine (DAB) was employed
as chromogen.The primary antibody usedwas Ki-67 Antigen
Clone MIB-1 M7240. After implementation of the visualiza-
tion system, the sections were counterstained with hema-
toxylin for 1 minute, washed with tepid water, dehydrated in
ethyl alcohol of different concentration (70%, 96% and 100%),
and then rinsed in a xylene substitute. Finally, coverslips were
mounted in GLC Mounting Medium. Washes between each
step were performed using Dako Wash Buffer 10x S 3006.
2.4. Evaluation of Proliferative Index. The evaluation of Ki-
67 expression on tumor cells was performed using present
information provided in the available literature. The expres-
sion was evaluated two independent pathologists N.J. and
A.D. Ki-67 expression was counted as a percentage. The
evaluation was carried out using the following procedure:
quantification of structures was performed by the Alphelys
Spot Browser 2 integrated system consisting of a software-
controlled (Alphelys Spot Browser 2.4.4) motorized micro-
scope (Nikon Eclipse 50i) with a mounted digital camera
(Microvision CFW-1310C, 24 bits, 1360x1024 pixel resolu-
tion).
The system was calibrated by the Nazca software (Micro-
vision Instruments, France) which determines the size of a
pixel for each lens (0.3311 𝜇m for 20x lens and 3.320 𝜇m for
2x).
After having taken overview images of the slides at 20x
magnification, images of the selected areas were taken at 200x
magnification to be analyzed with image analysis software
tools, under constant adjustments of camera and microscope
settings.
Digital image analysis detects objects based on color
(wavelength, intensity, and saturation), groupings and mor-
phological features (size and shape). Objects are marked
with colors, which enables a control and correction of the
detection process.
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Table 1: Patient group-adjusted frequency of grouped proliferative index values and histological tumor grade.
Tumor proliferative index
Histological tumor grade Low (≤34) High (>34) Total
0 5 4 9
1 7 11 18
2 13 27 40
3 9 2 11
Total 34 44 78
Table 2: Patient group-adjusted frequency of grouped proliferative index values by diagnosis.
Tumor proliferative index
Diagnosis Low (≤34) High (>34) Total
Malignant laryngeal neoplasm 30 38 68
Malignant laryngeal neoplasm+ regional lymph node metastases 4 6 10
Total 34 44 78
Table 3: Patient group-adjusted frequency of grouped proliferative index values and the stage of the disease.
Tumor proliferative index
Stage Low (≤34) High (>34) Total
Early 14 22 36
Advanced 20 22 42
Total 34 44 78
Table 4: Patient group-adjusted frequency of grouped proliferative index values and treatment outcome.
Tumor proliferative index
Treatment outcome Low (≤34) High (>34) Total
Alive 21 29 50
Deceased 13 15 28
Total 34 44 78
For this purpose, a detection algorithm that specifies
conditions for detection of objects of interest quantification
has been developed.
During the detection process, the software automatically
performs the measurement of detected objects and calcula-
tion of default parameters, in this case the number of positive
and negative tumor cell nuclei.
2.5. Statistical Analysis. Statistical analysis of the collected
data was performed using Statistica software package (Ver-
sion 10.0, StatSoft Inc. Tulsa, OK, USA). Appropriate statisti-
cal tests were employed to analyze the collected data, with a
statistical significance level of p<0.05 to form a conclusion.
3. Results
The patients were divided into two groups according to Ki-
67 proliferative index values: a low Ki-67 index group (Ki-
67≤34) and high Ki-67 index group (Ki-67 >34).
Table 1 shows the frequency of low and high Ki-67
proliferative index in relation to histological grade. Statistical
analysis of the data contained in the table reveals a statistically
significant correlation between histological tumor grade and
the value of the Ki-67 proliferative index (Pearson’s 𝜒2 test,
𝜒
2 =9.22, and p=0.026), with significant departures from
the expected frequencies for histological grades 2 and 3. In
grade 2 tumors, patients with the proliferative index >34
significantly prevail, whereas in grade 3 patients, there is a
significant prevalence of the proliferative index ≤34.
Table 2 shows patient group-adjusted proliferative index
values in relation to diagnosis. Analysis of the data contained
in the table indicates that there is no correlation between
diagnosis and proliferative index (Pearson’s 𝜒2 test, 𝜒2 =0.60,
p=0.806).
Table 3 displays the patient group-adjusted frequency of
grouped proliferative index values in relation to the stage of
the disease. Analysis of the data contained in this table reveals
no correlation between the two sets of data (Pearson’s 𝜒2 test,
𝜒
2 =0.63, p=0.438).
Table 4 shows the patient group-adjusted frequency of
grouped proliferative index values with respect to treatment
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outcome. Analysis of the data contained in this table demon-
strates that no correlation exists between the two sets of data
(Pearson’s 𝜒2 test, 𝜒2 =0.14, p=0.705).
4. Discussion
Cell proliferation is among the most important factors
involved in the biological process of oncogenesis. Over the
last few years, there has been a significant progress in the
development of a number of antibodies associated with
proliferation factors. In laryngeal carcinoma, Ki-67 is the
most widely used factor of cell proliferation. There is no
clear cut-off that can be used to determine low or high
proliferation rates. In our study, we have used the mean value
calculated according to the available literature data [8, 10, 18–
20]. Patients with Ki-67 levels under and equal to 34% were
assigned to the low Ki-67 group, whereas the remaining ones
were assigned to the high Ki-67 group.
In our study, we observed the relationship between the
histological grade and expression of the proliferation factor
Ki-67. A majority of studies to date advocate a positive
correlation between the expression of the Ki-67 proliferative
index and histological grade.Mondal et al. found a significant
correlation between Ki-67 expression and histological grade
[21]. Cui et al. performed a retrospective analysis of a large
sample size of 555 cases of vocal cord leukoplakia, consisted
of keratosis, hyperplasia, dysplasia, and malignancies. The
expression of the proliferation factor Ki-67 was significantly
associated with histopatological grade. All of the malignant
cases in this patient cohort were found positive in Ki67
staining [22]. Pastuszewski et al. also provided evidence of an
increased expression of Ki-67 related to an increase in histo-
logical grade, with the highest levels having been detected in
histological grade 3 [23]. Sarafoleanu et al. confirmed a statis-
tically significant positive correlation between the expression
of the proliferation factor Ki-67 and histological grade [24].
Our study produced unexpected results as, based on current
knowledge, the assumption had been that the proliferation
index would increase with an increase in histological grade.
In our study, uncorroborated positive correlation between
a higher histological grade and a higher Ki-67 level further
suggests the relevance of both the Ki-67 proliferative index
assessment and histological grading. However, histological
grading is a subjective method, and this quality is considered
to be its disadvantage. Ki-67 proliferation factor values should
therefore be investigated along with the proliferative index
and other parameters in order to, taking into account the
overall results, draw conclusions on the clinical course and/or
treatment.
Previous studies on the proliferative index in relation to
the clinical course and treatment outcome have produced
markedly contradictory results. The study by Cordes et al.
demonstrated a 5-year-survival rate of 84% for patients with
low proliferative index, whereas the survival rate for patients
with high proliferative index was 47.18% [8]. In contrast to
the above, the study by Teppo et al reported that Ki-67
did not significantly affect the prognosis of laryngeal cancer
[25]. Research conducted on 2077 patients demonstrated
a correlation between high proliferative index and poor
prognosis, whereas another one that included 1,212 patients
refuted the results of the previous study [6].
Our study did not provide evidence of any correlation
between proliferative index and either stage of the disease
or treatment outcome, which to some extent complies with
published results. Pastuszewski et al. also did not find any
relationship between the expression of Ki-67 proliferative
index and stage of the disease, but demonstrated a signifi-
cantly shortened survival in patients with a high expression
of Ki-67 [23]. In a study conducted on a cohort of 108
patients with malignant neoplasms of the larynx, Re et al.
showed a significantly lower expression of Ki-67 in the early
stage of the disease as compared to the advanced stage
[26].
With a view to the above results, we may conclude
that neither Ki-67 nor its role in the treatment of patients
with malignant neoplasms of the larynx has been precisely
defined. Further studies are needed to clarify the role of Ki-
67 and enable definite conclusions about its utility in everyday
clinical practice.
5. Conclusion
Precise diagnosis and prediction of the clinical course in
patients with malignant neoplasms of the larynx represent
a great challenge. Great efforts are made to identify an
ideal proliferation marker that might indicate the clinical
course and treatment outcome of patients with malignant
neoplasms. The general properties of such a marker should
include simple detection, unambiguous results as regards the
outcome and clinical course of the disease, and affordabil-
ity. The use of such a reliable proliferation marker would
enable modification of the current guidelines in order to
ensure more accurate patient treatment and avoid both
undertreatment or overtreatment and excessive diagnostic
testing. As present results related to Ki-67 have not yet been
substantiated enough and have as well been contradictory, we
may conclude that additional investigations are required to
more precisely define Ki-67 and its role in the treatment of
patients with malignant neoplasms of the larynx.
Data Availability
Thedata about tissue samples and data frompatients’ medical
history used to support the findings of this study are restricted
by the Ethics board of Clinical Hospital Center Rijeka in
order to protect patient privacy. Data are available from Jelena
Vukelic (jl.vukelic@gmail.com), for researchers whomeet the
criteria for access to confidential data.
Ethical Approval
The study observed the four basic ethical principles (personal
integrity—autonomy, justice, beneficence, and nonmalefi-
cence) and the ones that are deduced from them (privacy,
BioMed Research International 5
trust). The study was conducted in accordance with the
Nuremberg Code, the most recent revision of the Decla-
ration of Helsinki, and other relevant documents. Medical
information was collected in accordance with the bioethical
standards, and the privacy (medical confidentiality) of study
patients as well as their data confidentiality and protection
was ensured.
Conflicts of Interest
The authors declare that they have no conflicts of interest to
the publication of this article.
Acknowledgments
The research has been partly financed by University of Rijeka
as a part of the project “Molecular markers in precancerous
lesions and invasive cancers of the larynx,” grant number
13.06.2.2.59.
References
[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,” CA:
A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
[2] M. J. Ashraf, M. Maghbul, N. Azarpira, and B. Khademi,
“Expression of Ki67 and P53 in primary squamous cell carci-
noma of the larynx,” Indian Journal of Pathology and Microbiol-
ogy, vol. 53, no. 4, pp. 661–665, 2010.
[3] A. Ferlito, L. D. R. Thompson, A. Cardesa et al., “The impor-
tance of histological types for treatment and prognosis in
laryngeal cancer,” European Archives of Oto-Rhino-Laryngology,
vol. 270, no. 2, pp. 401–403, 2013.
[4] M.R. Issa, S. E. Samuels, E. Bellile, F. L. Shalabi, A. Eisbruch, and
G. Wolf, “Tumor volumes and prognosis in laryngeal cancer,”
Cancers (Basel), vol. 7, no. 4, pp. 2236–2261, 2015.
[5] R. Sahoo, V. Chittibabu, G. Patil et al., “Relationship between
molecular markers and treatment response in a retrospective
cohort of Indian patientswith primary carcinomaof the larynx,”
Oral Oncology, vol. 45, no. 12, pp. e216–e221, 2009.
[6] A. Pich, L. Chiusa, and R. Navone, “Prognostic relevance of cell
proliferation in head and neck tumors,”Annals of Oncology, vol.
15, no. 9, pp. 1319–1329, 2004.
[7] M. Kapral, B. Strzalka-Mrozik, M. Kowalczyk et al., “Transcrip-
tional activities of histone H3, cyclin D1 and claudin 7 encoding
genes in laryngeal cancer,” European Archives of Oto-Rhino-
Laryngology, vol. 268, no. 5, pp. 709–714, 2011.
[8] C. Cordes, A.-K. Mu¨nzel, P. Rudolph, M. Hoffmann, L. Ivo, and
S. Gottschlich, “Immunohistochemical staining of Ki-67 using
the monoclonal antibody Ki-sll is a prognostic indicator for
laryngeal squamous cell carcinoma,”Anticancer Reseach, vol. 29,
no. 4, pp. 1459–1466, 2009.
[9] W. A. Ahmed, K. Suzuki, Y. Imaeda, and Y. Horibe, “Ki-67,
p53 and epidermal growth factor receptor expression in early
glottic cancer involving the anterior commissure treated with
radiotherapy,” Auris Nasus Larynx, vol. 35, no. 2, pp. 213–219,
2008.
[10] R. G. Bonhin, G. M. de Carvalho, A. C. Guimara˜es et al.,
“Histologic correlation of expression of Ki-67 in squamous
cell carcinoma of the glottis according to the degree of cell
differentiation,” Brazilian Journal of Otorhinolaryngology, vol.
80, no. 4, pp. 290–295, 2014.
[11] M. De Vincentiis, P. Di Cello, F. Censi et al., “Immunohis-
tochemical expression of fatty acid synthase, Ki-67 and p53
in squamous cell carcinomas of the larynx,” The International
Journal of Biological Markers, vol. 23, no. 3, pp. 176–181, 2008.
[12] Y. Bai, Y. Shao, H. Li, W. Xue, F. Quan, and S. Wu, “Ki-67 is
overexpressed in human laryngeal carcinoma and contributes
to the proliferation of HEp2 cells,” Oncology Letters, vol. 12, no.
4, pp. 2641–2647, 2016.
[13] R.N. Kulagin, “Molecular prognosticmarkers of lymphogenous
metastasis of squamous cell carcinoma of the larynx (an
immuno-histochemical study),” Vestnik Otorinolaringologii,
vol. 5, pp. 11–14, 2011.
[14] O. Barutc¸u, M. Kara, A. Muratlı, O. Gu¨c¸lu¨, and S. Dereko¨y,
“Clinical significance of Ki-67, c-erbB-2 and E-cadherin expres-
sions in open partial laryngectomy patients,” Kulak Burun
Bogaz Ihtisas Dergisi, vol. 26, no. 5, pp. 283–292, 2016.
[15] M. F. Acikalin, U¨. O¨ner, N. Tel, O¨. Pas¸aog˘lu, H. C¸akli, and
E. C¸olak, “Prognostic significance of Ki-67 expression for
patients with laryngeal squamous cell carcinoma primarily
treated by total laryngectomy,” European Archives of Oto-Rhino-
Laryngology, vol. 261, no. 7, pp. 376–380, 2004.
[16] F. M. Gioacchini, M. Alicandri-Ciufelli, G. Magliulo, C. Rubini,
L. Presutti, and M. Re, “The clinical relevance of Ki-67 expres-
sion in laryngeal squamous cell carcinoma,” European Archives
of Oto-Rhino-Laryngology, vol. 272, no. 7, article 3117, pp. 1569–
1576, 2015.
[17] A. P. Concus, T. N. Tran, N. J. Sanfilippo, and M. D. DeLacure,
“Malignant laryngeal lesions,” in Current diagnosis & treatment
in otolaryngology head & neck surgery, A. Lalwani, Ed., pp. 456–
474, McGraw-Hill Medical, New York, NY, USA, 2011.
[18] K. Saarilahti,M.Kajanti,M.Kouri, L.-M.Aaltonen,K. Franssila,
and H. Joensuu, “Cyclin A and Ki-67 expression as predictors
for locoregional recurrence and outcome in laryngeal cancer
patients treated with surgery and postoperative radiotherapy,”
International Journal of Radiation Oncology, Biology, Physics,
vol. 57, no. 4, pp. 986–995, 2003.
[19] A. C. H. Lazaris, A. Rigopoulou, S. Tseleni-Balafouta et al.,
“Immunodetection and clinicopathological correlates of two
tumour growth regulators in laryngeal carcinoma,” Histology
and Histopathology, vol. 17, no. 1, pp. 131–138, 2002.
[20] C. Couture, H. Raybaud-Dioge`ne, B. Teˆtu et al., “p53 and Ki-
67 as markers of radioresistance in head and neck carcinoma,”
Cancer, vol. 94, no. 3, pp. 713–722, 2002.
[21] D. Mondal, K. Saha, C. Datta, U. Chatterjee, and A. Sengupta,
“Ki67, p27 and p53 Expression in Squamous Epithelial Lesions
of Larynx,” Indian Journal of Otolaryngology and Head & Neck
Surgery, vol. 65, no. 2, pp. 126–133, 2013.
[22] W. Cui,W. Xu, Q. Yang, and R.Hu, “Clinicopathological param-
eters associated with histological background and recurrence
after surgical intervention of vocal cord leukoplakia,”Medicine
(Baltimore), vol. 96, no. 22, Article ID e7033, 2017.
[23] W. Pastuszewski, P. Dziegiel, T. Krecicki et al., “Prognostic
significance of metallothionein, p53 protein and Ki-67 antigen
expression in laryngeal cancer,” Anticancer Reseach, vol. 27, pp.
335–342, 2009.
[24] D. Sarafoleanu, V. Postelnicu, C. Iosif, C. Manea, and C.
Sarafoleanu, “The role of p53, PCNA and Ki-67 as outcome
predictors in the treatment of laryngeal cancer,” Journal of
Medicine and Life, vol. 2, no. 2, pp. 219–226, 2009.
[25] H. Teppo, Y. Soini, J. Melkko, P. Koivunen, and O.-P. Alho,
“Prognostic factors in laryngeal carcinoma: The role of apop-
tosis, p53, proliferation (Ki-67) and angiogenesis,” APMIS-Acta
6 BioMed Research International
Pathologica, Microbiologica et Immunologica Scandinavica, vol.
111, no. 4, pp. 451–457, 2003.
[26] M. Re, A. Zizzi, L. Ferrante et al., “p63 and Ki-67 immunos-
tainings in laryngeal squamous cell carcinoma are related to
survival,” European Archives of Oto-Rhino-Laryngology, vol. 271,
















































































Submit your manuscripts at
www.hindawi.com
